MARKET

SGEN

SGEN

Seagen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

144.94
+0.18
+0.12%
Opening 11:12 04/21 EDT
OPEN
143.69
PREV CLOSE
144.76
HIGH
145.70
LOW
143.69
VOLUME
353.73K
TURNOVER
--
52 WEEK HIGH
213.94
52 WEEK LOW
134.51
MARKET CAP
26.28B
P/E (TTM)
43.98
1D
5D
1M
3M
1Y
5Y
Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
Zacks.com · 1d ago
Hodgkin’s Lymphoma Treatment Market Analysis, Impact of COVID-19 , Revenues and Regional Outlook | Forecast to 2027
Apr 20, 2021 (The Expresswire) -- Global ”Hodgkin’s Lymphoma Treatment Market“ 2020 industry research report gives Advancement strategies and plans are...
The Express Wire · 1d ago
Global Scleroderma Therapeutics Market 2021 - Increase in Demand Expected in Forecasted Year to 2025, Product Specification, Consumption Status, Industry Share, Top Manufacture with Types and Applications
Apr 20, 2021 (The Expresswire) -- Covid -19 Impact to global Scleroderma Therapeutics Market for 2015-2025. Global “Scleroderma Therapeutics Market” report...
The Express Wire · 1d ago
FDA accepts Seagen, Astellas' enfortumab vedotin applications in urothelial cancer
Under Real-Time Oncology Review ((RTOR)) pilot program, FDA has accepted for review Seagen (SGEN) and Astellas Pharma's (ALPMF) two supplemental Biologics License Applications (sBLA) for PADCEV (enfortumab vedotin-ejfv) in locally advanced
Seekingalpha · 2d ago
BRIEF-Seagen, Astellas Report U.S. FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV
reuters.com · 2d ago
Astellas And Seagen Announce US FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (NASDAQ:SGEN) today announced the U.S. Food and Drug Administration (FDA) filed two supplemental
Benzinga · 2d ago
Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
and , /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) filed two supplemental Biologics License Application (sB...
PR Newswire - PRF · 2d ago
Seagen, Astellas' Biologics License Applications for Bladder Cancer Drug Candidate Accepted for Priority Review by FDA
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SGEN. Analyze the recent business situations of Seagen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SGEN stock price target is 192.06 with a high estimate of 254.00 and a low estimate of 145.00.
EPS
Institutional Holdings
Institutions: 683
Institutional Holdings: 170.36M
% Owned: 93.96%
Shares Outstanding: 181.31M
TypeInstitutionsShares
Increased
171
6.95M
New
137
4.93M
Decreased
129
5.68M
Sold Out
64
1.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.49%
Pharmaceuticals & Medical Research
+0.99%
Key Executives
Chairman/Director/President/Chief Executive Officer
Clay Siegall
Chief Financial Officer
Todd Simpson
Executive Vice President/General Counsel/Secretary
Jean Liu
Executive Vice President
Chip Romp
Chief Technology Officer
Vaughn Himes
Other
Roger Dansey
Other
Brian Donnelly
Lead Director/Independent Director
Felix Baker
Independent Director
David Gryska
Independent Director
Marc Lippman
Independent Director
Ted Love
Independent Director
John Orwin
Independent Director
Alpna Seth
Independent Director
Nancy Simonian
Independent Director
Daniel Welch
No Data
About SGEN
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.

Webull offers kinds of Seagen Inc stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGEN stock methods without spending real money on the virtual paper trading platform.